---
title: "GBIO.US (GBIO.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/GBIO.US/news.md"
symbol: "GBIO.US"
name: "GBIO.US"
parent: "https://longbridge.com/en/quote/GBIO.US.md"
datetime: "2026-05-20T11:58:44.022Z"
locales:
  - [en](https://longbridge.com/en/quote/GBIO.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/GBIO.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/GBIO.US/news.md)
---

# GBIO.US (GBIO.US) — Related News

### [07:45 ETAdvaita Bio Launches iSCanGuide™: Unified Single-Cell and Spatial Transcriptomics Analysis, Powered by GPU-Accelerated Infrastructure](https://longbridge.com/en/news/285544017.md)
*2026-05-07T11:45:38.000Z*
> Advaita Bio has launched iSCanGuide, a cloud-based platform designed to streamline single-cell and spatial transcriptomi

### [08:00 ETCGBIO Receives FDA 510(k) Clearance for Patient-Specific Titanium Implant 'EASYMADE TI'](https://longbridge.com/en/news/283996851.md)
*2026-04-24T12:00:40.000Z*
> CGBIO has received FDA 510(k) clearance for its patient-specific titanium implant, EASYMADE TI, marking the first instan

### [Oncotelic Therapeutics 2025 10-K: Net income $249.02M; EPS $0.59](https://longbridge.com/en/news/282896898.md)
*2026-04-15T20:35:02.000Z*
> Oncotelic Therapeutics reported a net income of $249.02 million for 2025, primarily due to a fair value gain on its GMP 

### [AllRock Bio begins patient dosing in Phase IIa ROCSTAR trial](https://longbridge.com/en/news/282408747.md)
*2026-04-10T09:25:54.000Z*
> AllRock Bio has initiated patient dosing in the Phase IIa ROCSTAR trial for ROC-101, an oral pan-ROCK inhibitor targetin

### [20:00 ETCGBIO Showcases Comprehensive Medical Device Portfolio at KIMES 2026 Achieves KRW 5.3 Billion in Contract Results](https://longbridge.com/en/news/281807631.md)
*2026-04-07T00:00:42.000Z*
> CGBIO, a biotechnology company specializing in regenerative medicine, showcased its medical device portfolio at KIMES 20

### [](https://longbridge.com/en/news/281689951.md)
*2026-04-04T16:03:03.000Z*
> Anthropic acquired AI drug development startup Coefficient Bio for $400 million

### [Anthropic buys biotech startup Coefficient Bio in $400M deal: reports](https://longbridge.com/en/news/281660846.md)
*2026-04-03T20:30:22.000Z*
> Anthropic has acquired biotech startup Coefficient Bio for $400 million in stock. This acquisition aligns with Anthropic